Atlas Trials

Octapharma

71 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Octapharma

RecordFirmDate
Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections (NCT07220915)Octapharma2026-06-10
Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure (NCT06429787)Octapharma2025-02-14
Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass (NCT06096116)Octapharma2024-08-21
Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks (NCT06361537)Octapharma2024-04-30
Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study (NCT05935358)Octapharma2023-11-28
Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients (NCT04929236)Octapharma2023-10-01
Active-control Randomized Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery (NCT05523297)Octapharma2022-11-30
Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery (NCT04918173)Octapharma2022-07-01
Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Age (NCT04953884)Octapharma2021-09-22
Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor (NCT04867837)Octapharma2021-09-01
Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases (NCT04640142)Octapharma2021-08-04
Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS) (NCT04508530)Octapharma2021-06-30
Safety and Efficacy of Fibryga in Congenital Fibrinogen Deficiency (NCT03793426)Octapharma2021-01-28
Observational, Retrospective Study to Evaluate Coagulation Changes and the Influence of Antithrombin III Treatment in Patients With Severe COVID-19 Infection (NCT04651400)Octapharma2020-10-19
Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study) (NCT04502030)Octapharma2020-10-05
Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD (NCT04052698)Octapharma2020-06-18
Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression (NCT04400058)Octapharma2020-06-01
Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP) (NCT03866798)Octapharma2020-01-21
Effectiveness and Tolerability of Eqwilate in Real-life Conditions (NCT04106908)Octapharma2019-11-27
Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases (NCT03939533)Octapharma2019-10-17
Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A (NCT04046848)Octapharma2019-07-03
Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment (NCT04053699)Octapharma2019-06-25
Study Evaluating Efficacy and Safety of Octanorm in Patients With Dermatomyositis (NCT03686969)Octapharma2018-08-02
Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency (NCT03385395)Octapharma2018-07-01
Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq (NCT03344003)Octapharma2018-06-28
Observational Study of the Use of octaplasLG®. (NCT03369314)Octapharma2018-03-02
Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients (NCT03695978)Octapharma2018-02-13
Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A (NCT03376516)Octapharma2017-11-22
Use of Prothrombin Complex Concentrate in Patients Admitted in Emergency Care Units for Severe Bleeding While Receiving Oral Anticoagulants (NCT03320603)Octapharma2017-10-13
Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy (NCT02638207)Octapharma2017-09-27
The Effect of Subcutaneous Immunoglobulin Gammanorm on the Distribution of IgG Subclasses and on Immunity of Patients With Secondary Immunodeficiency (NCT03369301)Octapharma2017-09-25

Track Octapharma automatically

Every clearance here is in the API, with alerts when new ones post.